A phase II study of irinotecan as single agent in the third-line treatment of unresectable or metastatic gastric cancer.

e16084Background: There is no relative standard chemotherapeutic regimen in the third line therapy except oral anti-angiogenesis drug-Apatinib. This study was designed to determine the efficacy and...